参考文献/References:
1 Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012 [J]. CA Cancer J Clin, 2015, 65(2): 87-108.
2 Nelson RL, Turyk M, Kim J, et al. Bone mineral density and the subsequent risk of cancer in the NHANES I follow-up cohort [J]. BMC Cancer, 2002, 2(1): 22.
3 Chen CW, Tsai HL, Yeh YS, et al. Osteoporosis self-assessment Tool for asians as a simple risk index of identifying a poor prognosis in women surgically treated for colorectal cancer [J]. J Surg Res, 2013, 181(2): 242-249.
4 Harris TJ, Tepass U. Adherens junctions: from molecules to morphogenesis [J]. Nat Rev Mol Cell Biol, 2010, 11(7): 502-514.
5 Mandai K , Rikitake Y , Shimono Y , Takai Y . Afadin/AF-6 and canoe: roles in cell adhesion and beyond [J]. Prog Mol Biol Transl Sci 2013 ;116 433-54.
6 Moritz A, Li Y, Guo AL, et al. Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases [J]. Sci Signal, 2010, 3(136): ra64.
7 Elloul S, Kedrin D, Knoblauch NW, et al. The adherens junction protein afadin is an AKT substrate that regulates breast cancer cell migration [J]. Mol Cancer Res, 2014, 12(3): 464-476.
8 Prevention and management of osteoporosi [J]. World Health Organ Tech Rep Ser. 2003, 921: 1-164
9 Takai Y, Nakanishi H. Nectin and afadin: novel organizers of intercellular junctions [J]. J Cell Sci, 2003, 116(1): 17-27.
10 Deshpande AJ, Chen LY, Fazio M, et al. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l [J]. Blood, 2013, 121(13): 2533-2541.
11 Fournier G, Cabaud O, Josselin E, et al. Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth [J]. Oncogene, 2011, 30(36): 3862-3874.
12 Xu, Y, Chang R,Peng Z,Wang Y, et al. Loss of polarity protein AF6 promotes pancreatic cancer metastasis by inducing Snail expression [J]. Nat Commun, 2015: 7184.
13 Yamamoto, T. Loss of AF-6/afadin induces cell invasion,suppresses the formation of glandular structures and might be a predictive marker of resistance to chemotherapy in endometrial cancer [Z]. 2015: 275.
14 Piguet AC, Dufourt JF. PI(3)K/PTEN/AKT pathway [J]. J Hepatol, 2011, 54(6): 1317-1319.
15 Cantley CL. The phosphoinositide 3-kinase pathway [J]. Sci, 2002: 296(5573): 1655-1657.
16 Vivanco I, Sawyers CL. The phosphatidylinositol 3-Knase AKT pathway in human cancer [J]. Nat Rev Cancer, 2002, 2(7): 489-501.
17 Xi JC, Zang HY, Guo LX, et al. The PI3K/AKT cell signaling pathway is involved in regulation of osteoporosis [J]. J Recept Signal Transduct Res, 2015, 35(6): 640-645.